Horizon begins phase four clinical trial of Genmab drug
Horizon Therapeutics enters phase four clinical trial of the drug Tepezza to learn more about its effects on patients with chronic Graves' ophthalmopathy. The company has reaped millions from the already FDA-approved drug.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
The drug Tepezza has already been celebrated by the pharmaceutical industry as the first FDA-approved drug for the treatment of thyroid eye disease, also known as Graves' ophthalmopathy. The company behind the drug, Horizon Therapeutics, is now eager to better understand the long-term use of the drug.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab drug becomes more accessible in the US
For subscribers
.jpg&w=384&q=75)
